CG Oncology Inc.
CGON NASDAQHealthcare ★★★★★Latest Earnings Below forecast↓
Date
Aug 6, 2026
ET
EPS Est.
-0.66
EPS Actual
-0.90
Revenue Est.
$360805
Revenue Actual
$1.2M
Next Earnings Report Date unconfirmed
Date
Nov 13, 2026 · Fri
Time
Your time zone matches ET
Pre-market(ET)
Fiscal Period
FY2026 Q3
EPS Est.
-0.86
Revenue Est.
$547684
Company Overview
CG Oncology Inc. (ticker CGON) is listed on NASDAQ with a market cap of about $7.04B. Its next earnings report (FY2026 Q3) is expected on Nov 13, 2026 (ET), Pre-market (date pending company confirmation), with consensus EPS of -0.86. In the last 9 reported quarters, EPS beat consensus estimates 2 times.
Actual EPS TrendRecently9Term · May 9, 2024 → Aug 6, 2026
May 9, 2024Range: -0.90 ~ -0.28Aug 6, 2026
Earnings History
| Date | Fiscal Period | EPS Est. | EPS Actual | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Aug 6, 2026 | -- | -0.66 | Below forecast↓-0.90 | $360805 | $1.2M |
| May 8, 2026 | -- | -0.58 | Below forecast↓-0.71 | $453034 | $1.1M |
| Feb 27, 2026 | -- | -0.61 | Above forecast↑-0.51 | $450538 | $2.3M |
| Nov 14, 2025 | -- | -0.56 | -0.57 | $59364 | $1.7M |
| Aug 8, 2025 | -- | -0.49 | -0.54 | $81620 | -- |
| May 13, 2025 | -- | -0.39 | Below forecast↓-0.45 | $118170 | $52000 |
| Mar 28, 2025 | -- | -0.41 | Below forecast↓-0.48 | $123950 | $456000 |
| Nov 14, 2024 | -- | -0.42 | -- | -- | -- |
| Aug 8, 2024 | -- | -0.42 | Above forecast↑-0.28 | -- | $111000 |
| May 9, 2024 | -- | -0.35 | -0.36 | -- | $529000 |
| Mar 26, 2024 | -- | -0.67 | -- | -- | -- |
Original Filings (SEC)
Quarterly10-Q · 2026-08-06 ↗
Earnings Release8-K · 2026-08-06 ↗
Quarterly10-Q · 2026-05-08 ↗
Earnings Release8-K · 2026-05-08 ↗
Annual10-K · 2026-02-27 ↗
Earnings Release8-K · 2026-02-27 ↗
Quarterly10-Q · 2025-11-14 ↗
Earnings Release8-K · 2025-11-14 ↗
Links point to the company's original filings on the U.S. Securities and Exchange Commission (SEC) website.
Report dates are US trading days (Eastern Time); EPS and revenue estimates are market consensus, in USD. This page is for reference only and does not constitute investment advice.
